Opposing impacts of HLA-G haplotypes PROMO-G010104-UTR-3 and PROMO-G010101b/c-UTR-4 on risk of recurrent implantation failure.


Journal

Reproductive biomedicine online
ISSN: 1472-6491
Titre abrégé: Reprod Biomed Online
Pays: Netherlands
ID NLM: 101122473

Informations de publication

Date de publication:
09 2023
Historique:
received: 05 03 2023
revised: 24 04 2023
accepted: 26 04 2023
medline: 8 9 2023
pubmed: 18 6 2023
entrez: 17 6 2023
Statut: ppublish

Résumé

The human leukocyte antigen (HLA) class Ib molecules HLA-F and HLA-G are implicated in pregnancy success, but how do HLA-G and HLA-F genetic polymorphisms impact recurrent implantation failure (RIF)? Prospective cohort study at a fertility clinic including a cohort of 84 women experiencing RIF and 35 IVF controls to assess the influence of HLA-G haplotypes and diplotypes and HLA-F single nucleotide polymorphisms (SNP) on RIF. Over-representation trends for HLA-F SNP genotypes rs1362126, rs2523405 and rs2523393, previously linked with a short time-to-pregnancy, were detected in female control groups compared with RIF patients with no identified pathology linked to infertility. The HLA-G promoter haplotype PROMO-G010101b/c linked with the HLA-G 3'-untranslated region (3'UTR) haplotype UTR-4, which previously has been associated with positive IVF outcome and pregnancy success, was less frequent in the RIF group. For RIF patients carrying the UTR-4 haplotype, the odds ratio (OR) was 0.27 (95% CI 0.12-0.66; P = 0.0044, P These results show that specific HLA-G haplotypes based on the promoter region and the 3'UTR are either associated with an increased risk of reduced fertility, including the manifestation of RIF, and lower chance of achieving pregnancy, or with a reduced risk of experiencing RIF.

Identifiants

pubmed: 37330336
pii: S1472-6483(23)00272-9
doi: 10.1016/j.rbmo.2023.04.016
pii:
doi:

Substances chimiques

HLA-G Antigens 0
3' Untranslated Regions 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103225

Informations de copyright

Copyright © 2023 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Auteurs

Henrieta Papúchová (H)

Department of Clinical Biochemistry, Centre for Immune Regulation and Reproductive Immunology (CIRRI), Zealand University Hospital, Denmark; Department of Clinical Medicine, University of Copenhagen, Denmark; The ReproHealth Research Consortium, Zealand University Hospital, Denmark.

Malene Hviid Saxtorph (MH)

Department of Clinical Medicine, University of Copenhagen, Denmark; The ReproHealth Research Consortium, Zealand University Hospital, Denmark; Department of Gynecology, Obstetrics and Fertility, Zealand University Hospital, Denmark.

Trine Hallager (T)

The ReproHealth Research Consortium, Zealand University Hospital, Denmark; Department of Pathology, Zealand University Hospital, Denmark.

Ida E Jepsen (IE)

Department of Clinical Medicine, University of Copenhagen, Denmark; The ReproHealth Research Consortium, Zealand University Hospital, Denmark; Department of Gynecology, Obstetrics and Fertility, Zealand University Hospital, Denmark.

Jens O Eriksen (JO)

The ReproHealth Research Consortium, Zealand University Hospital, Denmark; Department of Pathology, Zealand University Hospital, Denmark.

Gry Persson (G)

Department of Clinical Biochemistry, Centre for Immune Regulation and Reproductive Immunology (CIRRI), Zealand University Hospital, Denmark; Department of Clinical Medicine, University of Copenhagen, Denmark; The ReproHealth Research Consortium, Zealand University Hospital, Denmark.

Tina Funck (T)

Department of Clinical Biochemistry, Centre for Immune Regulation and Reproductive Immunology (CIRRI), Zealand University Hospital, Denmark; Department of Clinical Medicine, University of Copenhagen, Denmark; The ReproHealth Research Consortium, Zealand University Hospital, Denmark.

Iben Weisdorf (I)

Department of Clinical Biochemistry, Centre for Immune Regulation and Reproductive Immunology (CIRRI), Zealand University Hospital, Denmark; Department of Clinical Medicine, University of Copenhagen, Denmark; The ReproHealth Research Consortium, Zealand University Hospital, Denmark.

Nicholas Macklon (N)

Department of Clinical Medicine, University of Copenhagen, Denmark; The ReproHealth Research Consortium, Zealand University Hospital, Denmark; Department of Gynecology, Obstetrics and Fertility, Zealand University Hospital, Denmark; London Women's Clinic, London, UK.

Lise Grupe Larsen (LG)

The ReproHealth Research Consortium, Zealand University Hospital, Denmark; Department of Pathology, Zealand University Hospital, Denmark.

Thomas Vauvert F Hviid (TVF)

Department of Clinical Biochemistry, Centre for Immune Regulation and Reproductive Immunology (CIRRI), Zealand University Hospital, Denmark; Department of Clinical Medicine, University of Copenhagen, Denmark; The ReproHealth Research Consortium, Zealand University Hospital, Denmark. Electronic address: tvh@regionsjaelland.dk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH